Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump
Plus news about United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmaker sold its second priority review voucher for
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.